Navigation Links
MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
Date:12/21/2010

to address undermet patient needs in neurology. The Company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, available at http://edgar.sec.gov. CONTACTS: Nicole FoderaroWCG(415) 215-5643nfoderaro@wcgworld.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
2. Lotus Pharmaceuticals Announces Change of Directors
3. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
4. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
5. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
6. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. John A. MacPhee Resigns From Strativa Pharmaceuticals
8. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
9. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)... May 21, 2015 ... - Zwecks Leistungsvergleich zur Expertise und ... EG-Mitgliedstaaten verwiesen, in denen uneingeschränkt betriebsfähige ... Sie ein Aegate-Land: beispielsweise BELGIEN   ... Bekämpfung von Arzneimittelfälschungen (FMD) handelt es ...
Breaking Medicine Technology:Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its ... $175 million in unlawful profits from the sale of products that were ... , , ... , , ...
... ExpertRECALL, the leader in the field of recall logistics and ... recall logistics management in the food, drug and consumer products industries to ... with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis University ,s ...
Cached Medicine Technology:Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme Bodyshaping ... obstacle run that raised funds for multiple sclerosis. , ... reason we participated was to support people living with MS ... Bodyshaping. “One-hundred percent of the funds raised go to benefit ... only attended by eXtreme Bodyshaping staff, but members of the ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Add High-Quality prismatic ... Pixel Film Studios. , It's as simple as dragging and ... the included tool for full effect. , Including over ... high-dynamic range 5k sensors making this the ultimate bundle for ... flares included in this package are movie files designed for ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 The American ... exciting events in June. They will hold a webinar ... and a two-day class on Classical Chinese Medicine. , ... 3, Dr. Steve Given, the Dean of Clinical Education, ... the new First Professional Doctorate program. ACTCM is currently ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Following yesterday’s ... sale agreement with US-based health brand Nature’s Way, Marc ... brand. Retention of Ascenta Skin is an integral part ... excited about this opportunity to further develop Ascenta Skin ... , Ascenta Skin is a breakthrough, anti-aging skincare supplement ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... , , BATESVILLE, ... and Radianse today announced a strategic partnership agreement to integrate ... Nurse Call system. With this move, Hill-Rom intends to ... to remove financial and technical obstacles for health care customers ...
... , VIENNA, Va., Sept. 2 ... ), a developer of vaccines for the prevention and treatment of ... of Series K convertible notes (the "Notes"). The Notes, which ... August 2006, and were convertible into common stock. , , ...
... ... (SIAC) will host Measuring Study Endpoints in Multinational Clinical Trials: Outcomes Reported from the ... LA. , ... Horsham, PA (Vocus) September 2, 2009 --The Drug Information Association (DIA) Study ...
... , SOMERSET, N.J., Sept. 2 ... and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal ... and perennial allergic rhinitis (SAR and PAR). New ASTEPRO ... convenient once-daily dosing for patients who suffer from seasonal allergies. ...
... , PARSIPPANY, N.J., Sept. 2 The following is ... Communication about the safety review of orlistat: , , ... safety review of orlistat and liver-related serious adverse events. , , ... http://www.prnewswire.com/mnr/alli/39949/ , , It,s important consumers know ...
... , , TUCSON, Ariz., Sept. 2 ... Fletcher McCusker, Chairman and Chief Executive Officer, is scheduled to present an ... Conference on Wednesday, September 9, 2009 at The Four Seasons Hotel in ... is scheduled for 9:30 a.m. ET. The presentation will be broadcast ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: